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ABSTRACT
The effects of corticosteroids on bone mass in
patients with bronchial asthma (BA) are still contro-
versial. To elucidate whether steroid administration
may influence bone mineral content (BMC) and
bone mineral density (BMO) in women with BA, a
longitudinal study was designed for adult female
asthmatics receiving long-term steroid therapy. We
measured whole body BMC and lumbar BMO by
dual energy X-ray absorptiometry in 23 women with
BA and compared the results with those from 17
age-matched controls. Both patient and control
groups were followed up for at least 1 year (mean
(± SO) observation period 94 ± 33 weeks). We
divided the asthmatic patients into two groups on the
basis of the mode of steroid administration: (i) group
A consisted of 10 patients with low dose oral steroid
administration (prednisolone 5-10 mg daily); and
(ii) group B consisted of 13 patients with low dose
beclomethasone dipropionate (BOP) inhalation
therapy (BOP 400-800 mg daily). There were no
significant differences in both baseline values and
changes of BMC and BMO among the three groups.
These results demonstrate that asthmatic patients
show normal bone mass and that both low dose
steroid administration and BOP inhalation do not
significantly affect BMC in patients with BA over the
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period studied. We suggest that appropriate steroid
use does not augment bone mineral loss in
asthmatics.
Key words: beclomethasone dipropionate, body com-
position, osteoporosis, pulmonary function.
INTRODUCTION
Steroid therapy has been an important treatment of
bronchial asthma (BA).l Oral corticosteroid therapy is
adopted in severe chronic asthmatics in addition to the
use of inhaled steroids. Steroid administration is known to
be associated with secondary osteoporosis." but this
effect of corticosteroids on bone mineral content (BMC)
in patients with BA is not well estoblished.:' Studies on the
effects of steroid inhalation on bone turnover suggest that
steroids may depress bone formation and increase bone
resorptlon'-" Moreover, bone mineral density (BMD) has
been shown to be decreased during a period of corticos-
teroids inhalation for 3 months." In contrast, we have
previously studied BMC and the relationship between
BMC and steroid administration in BA,? and the results
indicated that asthmatic patients showed normal BMC
and that steroid administration did not correlate with
BMC.
The recent development of dual energy X-ray absorp-
tiometry (DXA) has made it possible to analyze body
composition, BMC, lean body mass (LEAN) and fat body
mass (FAT).8 Using this method, we reported body com-
positional changes associated with several chronic
pulmonary disecses.i-? In the present study, a longitudi-
nal study was designed for adult female asthmatics
receiving chronic steroid therapy to elucidate whether or
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not steroid administration affects bone mass in patients
with BA.
using a spirometer for computer processing (Chestac 25;
Chest Co. Ltd, Tokyo, Japan) and the ratio of FEV1to FVC
(FEV1/FVC) was calculated.
METHODS
Subjects
In the present study, 23 women with BA were studied.
Diagnosis of BA was made by the American Thoracic
Society's criteric.!" Patients were clinically stable with no
history of congestive heart failure, recent respiratory infec-
tion within the previous 4 weeks, malabsorption or
diabetes mellitus. All patients with BA were treated with
slow-release theophylline derivatives (200-800 mg/day).
Eighteen of 23 patients with BA were postmenopausal. We
divided the patients into two groups on the basis of steroid
administration. Group A consisted of 10 patients with oral
steroid administration, who were administered predniso-
lone 5-10 mg daily. Group B consisted of 13 patients who
were undergoing beclomethasone dipropionate (BOP)
inhalation therapy. A further group, group C, consisted of
17 age-matched controls used to compare changes in
bone mass. All asthmatics had been monitored for at least
1 year (mean (± SO) duration 94 ± 33 weeks). Re-exami-
nation of body composition measurements was performed
at the end of the observation period. Informed consent was
obtained from each subject for this protocol.
Pulmonary function tests
Slow vital capacity (VC), forced vital capacity (FVC) and
forced expiratory volume in 1 s (FEV1) were measured
Body composition measurements
The body composition of the patients was determined by
DXA (XR-26; Norland) using whole body absorptiometry
software version 2.0.1 . The coefficient of variation (preci-
sion) of measurements of BMC, LEAN and FAT by this
method was 2.2, 3.1 and 3.2%, respectively. A strong
linear correlation was obtained between bodyweight and
total body mass measured by XR-26 (r = 0.980).11 The
parameters of body composition were expressed in kg
and percentages of BMC, LEAN and FAT were calculated
by dividing each absolute value of body composition by
total body mass.
Bone mineral density (L2-4) was measured separately
and is expressed as the mean data from three measure-
ments. Compression fracture of vertebrae can cause
aberrations in data for BMD and these data were
excluded from the calculations. Body mass index (BMI)
was calculated by dividing bodyweight (kg) by squared
height (m2) .
Statistical analysis
All values are given as the mean ± SO. Statistical differ-
ences for variables of body composition and pulmonary
function were analyzed by ANOVA. P < 0.05 was consid-
ered to be statistically significant.
Table 1. Anthropometric data
Group C
(controls)
49.4 ± 6.4
153.0 ± 5.4
51.6 ± 5.5
22.2 ± 3.0
462 ± 150
Group B
(BOP inhalation)
----
58.8 ± 13.1
150.7 ± 4.9
48.7 ± 8.6
21.5 ± 3.7
2.30 ± 0.62
93.9 ± 22.4
1.48 ± 0.45
68.1 ± 11.8
Group A
(steroid p.o.)
----- ---- ----'------ ----
57.1 ± 13.1
150.7 ± 6.6
55.5 ± 13.6
24.2 ± 4.7
2.12 ± 0.45
87.6 ± 15.4
1.20 ± 0.31
65.0 ± 7.9
5.8 ± 2.4
Age (years)
Height (em)
Bodyweight (kg)
BMI
VC (L)
%VC
FEV1 (LIs)
FEV1/FVC (%)
Mean dose prednisolone (g)
Mean dose BOP (/-lg)
TotoI dose pred nisolone (g) 12. 1 ± 12.9
Total dose BOP (mg) 320 ± 181
Observation period (weeks) 89 ± 28 98 ± 37
-~------
BMI, body mass index; BDp, beclomethasone dipropionate; VC, vital capacity; FEV1, forced expiratory volume in 1 s; FVC-, forced vital
capacity.
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Table2. Baseline body composition analysis
Group C
(controls)
--~
1.9±0.4
3.9 ± 0.7
32.9 ± 3.4
65.4 ± 5.9
17.6 ± 4.3
34.6 ± 5.9
0.891 ± 0.186
Group B
(BOP inhalation)
1.7 ± 0.4
3.7 ± 0.8
30.2 ± 3.0
66.2 ± 8.3
16.1 ± 6.5
33.8 ± 8.3
0.792 ± 0.142
Group A
(steroid p.o.)
-------- ------
2.0 ± 0.5
3.8 ± 0.7
31.9±3.7
61.3 ± 8.8
21.7 ± 9.3
38.7 ± 8.8
0.906±0.161
BMC (kg)
%BMC (%)
LEAN (kg)
%LEAN (%)
FAT (kg)
%FAT (%)
BMO (g/cm 2)
---'------------~
Values are the mean ± SD.
BMC, bone mineral content, %BMC, per cent BMC per bodyweight; LEAN, lean body mass; %LEAN, per cent lean body mass per bodyweight; FAT,
fat mass; %FAT, per cent fat mass per bodyweight; BMD, bone mineral density of the second to fourth lumbar spine; BDp,beclomethasone dipropionate.
Table 3. Changes of bone mineral content and densityduring oral steroid and beclomethasone dipropionate inhalation in asthmatics
Group A
(steroid p.o.)
-41.4 ± 107.3
-28.5 ± 88.3
0.022 ± 0.067
Group C
(controls)
-------
0.2 ± 92.2
0.2 ± 92.2
-0.053 ± 0.145
Values are the mean ± SD. There were no significant differences in changes in BMC and BMD between the three groups.
BMC, bone mineral content; %BMC, per cent of BMC per bodyweight; BDp, beclornethcsone dipropionate.
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Fig. 1 Changes of bone mineral content (BMC) in asthmatic
patients with oral steroid administration (a) and beclomethasone
dipropionate inhalation (b) and controls (c). There was no signif-
icant difference in changes of BMC among the three groups.
Fig. 2 Changes of bone mineral density in the second to
fourth lumbar spine (BMO) in asthmatic patients with oral
steroid administration (a) and beclomethasone dipropionate
inhalation (b), and in controls (c). There was no significant dif-
ference in changes of BMO among the three groups.
RESULTS
Age, height, bodyweight, 8MI and pulmonary
function
As shown in Table 1, there was no significant difference in
age, height, bodyweight and BMI between the three
groups. There was no significant change in bodyweight
during the observation period (51.7 ± 11.3 and
53.2 ± 12.0 kg for baseline and re-examination, respec-
tively). In pulmonary function tests, VC, %VC, FEV1 and
FEV1/FVC of group A subjects were not significantly differ-
ent from values obtained for group B subjects. No
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significant changes were seen in pulmonary function tests
during the period of observation. There was no significant
difference in the duration of the observation period
between groups A and B (89 ± 28 and 98 ± 37 weeks,
respectively).
Body composition
Baseline variables of body composition are shown in
Table 2. There were no significant differences in BMC,
FAT and LEAN between the three groups.
Changes in BMC and BMO are shown in Table 3.
There were no significant differences between the three
groups in changes in BMC and BMO during oral
steroid administration or BOP inhalation for at least
1 year (Figs 1,2).
In 16 postmenopausal asthmatics, there were no
significant changes in BMC and BMO between groups
A and B during the observation period.
Relationship between BMC and age,
anthropometric variables, pulmonary
function and steroid therapy
In the coefficient of correlation between BMC and age,
anthropometric variables and pulmonary function, BMC
was significantly correlated with age or bodyweight in
patients with BA (r = 0.64, P < 0.001 and r = 0.57,
P < 0.001, respectively). There was no significant corre-
lation of BMC with mean daily dose or total dose of
steroid administration and the duration of steroid therapy.
DISCUSSION
Our results demonstrate that there is no significant differ-
ence in both baseline values and changes of BMC
between asthmatic women with steroid administration
and age-matched controls.
Because BA is defined as an inflammatory process.'
steroid therapy has played an important role in the
treatment of asthma. Systemic corticosteroid therapy is
frequently required for the treatment of asthma.
However, osteoporosis is a well-known adverse effect of
systemic steroid odrninistrotion.? Suggested mecha-
nisms of corticosteroid-induced bone mineral loss
include direct effects on bone cells, alterations in
calcium absorption and renal handling of calcium and
abnormalities in the secretion of sex horrnones.vv'?
However, the effects of corticosteroids on BMC in BA
are still controversiol.v"
We have previously studied the relationship between
BMC and steroid administration in BA and the results
indicated that asthmatic women showed normal BMC
and that steroid administration was not responsible for
bone mineral loss in patients with BA.7 In the present
study, there was no significant correlation of BMC and
BMO with either the mean daily dose or the total dose of
steroid administration and the duration of steroid therapy.
Furthermore, there was no significant difference in
changes in either BMC or BMO during oral steroid
administration and BOP inhalation over a period of at
least 1 year between the three groups.
The incidence of steroid-related osteoporosis is not
clear. Adinoff studied bone disease in 128 patients with
BA and found that long-term steroid therapy in asthmatic
patients was associated with a decreased trabecular bone
density and an increased prevalence of rib and vertebral
Irocture.? Subjects with high bone remodeling rates, such
as children and postmenopausal women, are at high risk
of steroid-induced bone mineral loss.P Furthermore,
studies on the effects of steroid inhalation on bone
turnover indicate depressed serum osteocalcin, a marker
of osteoblast activity, and increased hydroxyproline output
in urine, suggesting that steroids may depress bone for-
mation and increase bone resorption." Nagasaka et 01.
also indicated a decrease of serum osteocalcin levels,
urinary pyridinoline and deoxypyridinolone, while treat-
ment-related bone mineral loss was not observed in cases
being treated with oral steroids.'?
Ooi et a/. studied the effects of steroids on BMO in
Japanese patients with BA.6 They showed a significant
negative correlation between BMO and the total dose of
prednisolone and between BMO and the duration of
prednisolone treatment. Compared with baseline values,
after steroid treatment BMO was significantly decreased.
These findings suggest that the reduction in BMO in asth-
matics is related to the total dose of prednisolone and
the duration of therapy. Furthermore, during a cross-
sectional study, Ip et 01. found a significant decrease in
BMO in women using inhaled steroids (BOP) in average
daily doses of 1100 mg/day. In female patients with BA,
BMO was inversely correlated with the daily inhaled
steroid dose.!"
Why steroids did not affect bone mass in patients with
BA in the present study is not known. However, we
strongly suspect an improvement of activity of daily life
(AOL) and bodyweight gain as reasons for this. Because
of the prevention from ah irlfldrnnidtory process of
BA, systemic corticosteroid therapy is required for the
treatment of severe chronic asthma. 13 Steroid therapy
improves pulmonary function and increases the degree of
ADL.3 The role of physical activity as a possible factor in
bone mineral loss was unclear in the present study.
However, it has been demonstrated that activity, in the
form of exercise programs, could reduce the loss of total
body calcium in postmenopausal women. Longitudinal
studies have shown that inactivity will increase urinary
calcium output and bone mineral loss. A regular exercise
program, such as walking, is encouraged as a general
preventive measure against osteoporosis.P We have also
found that changes in BMC are significantly correlated
with 12 min walking distance in patients with chronic
obstructive pulmonary diseose."
It is well known that bone mass is responsible for
bodyweiqht.!" In the present study, there was a signifi-
cant correlation between BMC and bodyweight in
asthmatic patients. Steroid-dependent bodyweight gain
may be responsible for maintaining bone mass.
However, bodyweight was not significantly correlated
with either the total dose of steroid administered or the
duration of steroid therapy. Moreover, bodyweight did
not significantly increase at least 1 year after steroid
administration.
Another possible explanation of our results would be
that our steroid-dependent asthmatics required relatively
low daily doses of steroids (below 10 mg/day pred-
nisolone). It is generally accepted that larger daily doses
of prednisolone (above 7.5 mg/day) or cumulative doses
(over 109) and longer treatment is associated with
greater bone mineral IOSS.13,17 There were no significant
correlations of BMC with either the mean daily dose or
the total dose of steroid administered and the duration of
steroid therapy. In the present study, we suggest that
appropriate steroid use does not augment bone mineral
loss in asthmatics.
Newly developed DXA made it possible to analyze body
composition, BMC, LEAN and FAT.8 We can measure
whole body BMC and regional BMD precisely and easily.
Several studies have suggested that DXA is accurate and
reliable for the measurement of calcium and fat
content. 18,19 Therefore, DXA may also be of practical use
for the longitudinal assessment of weight chonqe.'?
The limitations of the present study need to be men-
tioned. First, with the small sample size, we could not
exclude a type 2 error. However, we suspect that this is not
likely because while five of 10 patients in group A and
seven of 13 patients in group B showed a decrease in
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BMC after steroid therapy, the remaining asthmatic
patients (almost half) exhibited an increase. These results
strongly suggest that steroids do not always affect bone
mass. Second, group C consisted of normal subjects,
rather than asthmatics without steroid therapy, as a
control group. We wanted to compare the change of
bone mass between asthmatic patients and normal con-
trols. Third, menopause influences bone mass in female
subjects. Because we had such a small sample popula-
tion, we could not evaluate the effects of menopause on
bone mass. In postmenopausal asthmatics, both BMC
and BMD did not significantly change during the obser-
vation period. Fourth, this is a longitudinal study but not a
cross-sectional one. There have not been many longitu-
dinal studies investigating changes in bone mass in
patients with BA. There is only one report that followed up
subjects for more than 1 year.20 While our follow-up
period was approximately 90 weeks, there was no differ-
ence among the three groups. However, it is necessary to
observe bone mass for longer periods to evaluate the
effects of steroids on bone mass in asthmatics.
These results demonstrate that asthmatic patients show
normal bone mass and that both low dose steroid admin-
istration and low dose BDP inhalation do not significantly
affect BMC in patients with BA for this study period. We
suggest that appropriate steroid use does not augment
bone mineral loss in asthmatics.
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